These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2528403)

  • 1. Cisplatin-associated hemolytic-uremic syndrome. Successful treatment with a staphylococcal protein A column.
    Watson PR; Guthrie TH; Caruana RJ
    Cancer; 1989 Oct; 64(7):1400-3. PubMed ID: 2528403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx.
    Thurnher D; Kletzmayr J; Formanek M; Quint C; Czerny C; Burian M; Kornek G
    Oncology; 2001; 61(2):143-6. PubMed ID: 11528253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemolytic-uremic syndrome associated with neoadjuvant chemotherapy in the treatment of advanced cervical cancer.
    Angiola G; Bloss JD; DiSaia PJ; Warner AS; Manetta A; Berman ML
    Gynecol Oncol; 1990 Nov; 39(2):214-7. PubMed ID: 1699855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report.
    Gradishar WJ; Vokes EE; Ni K; Panje WR
    Cancer; 1990 Nov; 66(9):1914-8. PubMed ID: 2224786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy: a report of a case and a review of the literature.
    Gardner G; Mesler D; Gitelman HJ
    Ren Fail; 1989; 11(2-3):133-7. PubMed ID: 2482985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange.
    Palmisano J; Agraharkar M; Kaplan AA
    Am J Kidney Dis; 1998 Aug; 32(2):314-7. PubMed ID: 9708619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Sandler S; Bonomi P; Taylor B; Showel J; Slayton R; Lerner H
    Cancer Treat Rep; 1984 Sep; 68(9):1163-5. PubMed ID: 6541095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A combination of radiotherapy and chemotherapy with platidiam and fluorouracil in patients with head and neck cancer].
    Shparyk IaV; Kravets AI; Bilyns'kyĭ BT; Kuftiak OF
    Lik Sprava; 1996; (3-4):153-7. PubMed ID: 9035857
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: cisplatin-induced hemolytic uremic syndrome.
    Khansur T; Kennedy A
    Am J Med Sci; 1991 Jun; 301(6):390-2. PubMed ID: 1645502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin-associated hemolytic uremic syndrome.
    Canpolat C; Pearson P; Jaffe N
    Cancer; 1994 Dec; 74(11):3059-62. PubMed ID: 7954269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy-associated hemolytic uremic syndrome--a case report].
    Kikuchi H; Kanamaru R
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1927-9. PubMed ID: 1519930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy--a case report and review of the literature.
    van der Heijden M; Ackland SP; Deveridge S
    Acta Oncol; 1998; 37(1):107-9. PubMed ID: 9572663
    [No Abstract]   [Full Text] [Related]  

  • 14. [Drug induced hemolytic uremic syndrome].
    Ito K; Komatsu Y
    Nihon Rinsho; 1993 Jan; 51(1):204-9. PubMed ID: 7679450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
    J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of chemotherapy (cisplatin and 5-FU) and radiotherapy in the management of advanced or recurrent head and neck cancer: a phase II study.
    Grimaldi A; Merlano M; Benasso M; Margarino G; Scasso F; Corvò R; Rosso R
    Chemioterapia; 1986 Oct; 5(5):356-9. PubMed ID: 3791484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
    Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha.
    Ohashi N; Yonemura K; Sugiura T; Isozaki T; Togawa A; Fujigaki Y; Yamamoto T; Hishida A
    Am J Kidney Dis; 2003 Mar; 41(3):E10. PubMed ID: 12613003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of polychemotherapy with cisplatin, methotrexate and 5-fluorouracil in inoperable forms of squamous cell cancer of the head and neck area].
    Karaseva VV; Stepanov VG; Korolev VV
    Vopr Onkol; 1992; 38(2):205-8. PubMed ID: 1300707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I-II trial of cisplatin and dichloromethotrexate in squamous cell cancer of the head and neck.
    Wheeler RH; Natale RB; Roshon SG; Baker SR
    J Clin Oncol; 1984 Jul; 2(7):831-5. PubMed ID: 6539813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.